Floatz logo

Atezolizumab

Mycosis Fungoides/Sezary Syndrome

European Organisation for Research and Treatment of Cancer - EORTCmonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Mycosis Fungoides/Sezary Syndrome cohort.

Asset / SponsorPhaseRating
Romidepsin
Northwestern University
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Pembrolizumab
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
MOGAMULIZUMAB
University of Michigan Rogel Cancer Center
Phase 2B

View all 29 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →